Sarepta Therapeutics, a leading biopharmaceutical company, has provided an important update on the potential approval of its groundbreaking gene therapy for Duchenne muscular dystrophy (DMD). The U.S. Food and Drug Administration (FDA) has made the decision to delay its verdict on accelerated approval for the…